LONG ISLAND - Michael, a 48-year-old from Suffolk County, is suing Ozempic's manufacturer for loss of vision. Michael, who opted out of sharing his surname, says that the loss of sight began after his ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down ...

Denmark’s economic growth, which was driven by what economists described as an “exceptional surge” in pharmaceutical exports, ...

He’s the CEO of Danish pharmaceutical firm Novo Nordisk — best known as the maker of Ozempic and Wegovy, the blockbuster diabetes and weight-loss drugs-turned-cultural phenomena that have ...

Ozempic got US approval in 2017 ... "This is the largest ever." In 2023 Denmark ranked among Europe's fastest-growing economies, as GDP expanded by 2.5%, and half of that was driven by the ...

Could Ozempic be overtaken ... phones and Nokia has retreated to mostly providing back-end technology. For Denmark that would be an economic problem, but for the world the prospect of better ...

Denmark is home to Novo Nordisk (NYSE:NVO), the company behind Ozempic and Wegovy, two of the most in-demand drugs in the U.S. for weight loss and diabetes treatment. With demand for those drugs ...

Denmark is home to Novo Nordisk (NYSE:NVO), the company behind Ozempic and Wegovy, two of the most in-demand drugs in the U.S. for weight loss and diabetes treatment. With demand for those drugs ...